Screening of autoantibodies as biomarkers in the serum of renal cancer patients based on human proteome microarray
The autoantibody in patients’ serum can act as a biomarker for diagnosing cancer, and the differences in autoantibodies are significantly correlated with the changes in their target proteins. In this study, 16 renal cancer (RC) patients were assigned to the disease group, and 16 healthy people were...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
China Science Publishing & Media Ltd.
2022-12-01
|
| Series: | Acta Biochimica et Biophysica Sinica |
| Subjects: | |
| Online Access: | https://www.sciengine.com/doi/10.3724/abbs.2022189 |
| _version_ | 1797635374264090624 |
|---|---|
| author | Sun Yangyang Liu Chengxi Zhong Huidong Wang Chenguang Xu Haibo Chen Wei |
| author_facet | Sun Yangyang Liu Chengxi Zhong Huidong Wang Chenguang Xu Haibo Chen Wei |
| author_sort | Sun Yangyang |
| collection | DOAJ |
| description | The autoantibody in patients’ serum can act as a biomarker for diagnosing cancer, and the differences in autoantibodies are significantly correlated with the changes in their target proteins. In this study, 16 renal cancer (RC) patients were assigned to the disease group, and 16 healthy people were assigned to the healthy control (HC) group. The human proteome microarray consisting of>19,500 proteins was used to examine the differences in IgG and IgM autoantibodies in sera between RC and HC. The comparative analysis of the microarray results shows that 101 types of IgG and 25 types of IgM autoantibodies are significantly higher in RC than in HC. Highly responsive autoantibodies can be candidate biomarkers (e.g., anti-KCNAB2 IgG and anti-RCN1 IgM). Extensive enzyme-linked immunosorbent assay (ELISA) was performed to screen sera in 72 RC patients and 66 healthy volunteers to verify the effectiveness of the new autoantibodies. The AUCs of anti-KCNAB2 IgG and anti-GAPDH IgG were 0.833 and 0.753, respectively. KCNAB2 achieves high protein expression, and its high mRNA level is confirmed to be an unfavorable prognostic marker in clear cell renal cell carcinoma (ccRCC) tissues. This study suggests that the high-throughput human proteome microarray can effectively screen autoantibodies in serum as candidate biomarkers, and their corresponding target proteins can lay a basis for the in-depth investigation into renal cancer. |
| first_indexed | 2024-03-11T12:21:10Z |
| format | Article |
| id | doaj.art-d2d9f63b65ea46a7b94e3331ea099e1f |
| institution | Directory Open Access Journal |
| issn | 1672-9145 |
| language | English |
| last_indexed | 2024-03-11T12:21:10Z |
| publishDate | 2022-12-01 |
| publisher | China Science Publishing & Media Ltd. |
| record_format | Article |
| series | Acta Biochimica et Biophysica Sinica |
| spelling | doaj.art-d2d9f63b65ea46a7b94e3331ea099e1f2023-11-07T01:03:08ZengChina Science Publishing & Media Ltd.Acta Biochimica et Biophysica Sinica1672-91452022-12-01541909191610.3724/abbs.202218920d259ccScreening of autoantibodies as biomarkers in the serum of renal cancer patients based on human proteome microarraySun Yangyang0Liu Chengxi1Zhong Huidong2Wang Chenguang3Xu Haibo4Chen Wei5["Shenzhen Key Laboratory of Synthetic Genomics, Guangdong Provincial Key Laboratory of Synthetic Genomics, CAS Key Laboratory of Quantitative Engineering Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China","Department of Urology, Shenzhen Second People’s Hospital, the First Affiliated Hospital of Shenzhen University, International Cancer Center, Shenzhen University School of Medicine, Shenzhen 518039, China"]["State Key Laboratory of Chemical Biology and Drug Discovery, Food Safety and Technology Research Centre and Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hong Kong 999077, China"]["Department of Medicinal Chemistry, Shantou University Medical College, Shantou 515041, China"]["Shenzhen Key Laboratory of Synthetic Genomics, Guangdong Provincial Key Laboratory of Synthetic Genomics, CAS Key Laboratory of Quantitative Engineering Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China"]["Department of Urology, Shenzhen Second People’s Hospital, the First Affiliated Hospital of Shenzhen University, International Cancer Center, Shenzhen University School of Medicine, Shenzhen 518039, China"]["Shenzhen Key Laboratory of Synthetic Genomics, Guangdong Provincial Key Laboratory of Synthetic Genomics, CAS Key Laboratory of Quantitative Engineering Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China","Department of Urology, Shenzhen Second People’s Hospital, the First Affiliated Hospital of Shenzhen University, International Cancer Center, Shenzhen University School of Medicine, Shenzhen 518039, China"]The autoantibody in patients’ serum can act as a biomarker for diagnosing cancer, and the differences in autoantibodies are significantly correlated with the changes in their target proteins. In this study, 16 renal cancer (RC) patients were assigned to the disease group, and 16 healthy people were assigned to the healthy control (HC) group. The human proteome microarray consisting of>19,500 proteins was used to examine the differences in IgG and IgM autoantibodies in sera between RC and HC. The comparative analysis of the microarray results shows that 101 types of IgG and 25 types of IgM autoantibodies are significantly higher in RC than in HC. Highly responsive autoantibodies can be candidate biomarkers (e.g., anti-KCNAB2 IgG and anti-RCN1 IgM). Extensive enzyme-linked immunosorbent assay (ELISA) was performed to screen sera in 72 RC patients and 66 healthy volunteers to verify the effectiveness of the new autoantibodies. The AUCs of anti-KCNAB2 IgG and anti-GAPDH IgG were 0.833 and 0.753, respectively. KCNAB2 achieves high protein expression, and its high mRNA level is confirmed to be an unfavorable prognostic marker in clear cell renal cell carcinoma (ccRCC) tissues. This study suggests that the high-throughput human proteome microarray can effectively screen autoantibodies in serum as candidate biomarkers, and their corresponding target proteins can lay a basis for the in-depth investigation into renal cancer.https://www.sciengine.com/doi/10.3724/abbs.2022189renal cancerautoantibodybiomarkerhuman proteome microarray |
| spellingShingle | Sun Yangyang Liu Chengxi Zhong Huidong Wang Chenguang Xu Haibo Chen Wei Screening of autoantibodies as biomarkers in the serum of renal cancer patients based on human proteome microarray Acta Biochimica et Biophysica Sinica renal cancer autoantibody biomarker human proteome microarray |
| title | Screening of autoantibodies as biomarkers in the serum of renal cancer patients based on human proteome microarray |
| title_full | Screening of autoantibodies as biomarkers in the serum of renal cancer patients based on human proteome microarray |
| title_fullStr | Screening of autoantibodies as biomarkers in the serum of renal cancer patients based on human proteome microarray |
| title_full_unstemmed | Screening of autoantibodies as biomarkers in the serum of renal cancer patients based on human proteome microarray |
| title_short | Screening of autoantibodies as biomarkers in the serum of renal cancer patients based on human proteome microarray |
| title_sort | screening of autoantibodies as biomarkers in the serum of renal cancer patients based on human proteome microarray |
| topic | renal cancer autoantibody biomarker human proteome microarray |
| url | https://www.sciengine.com/doi/10.3724/abbs.2022189 |
| work_keys_str_mv | AT sunyangyang screeningofautoantibodiesasbiomarkersintheserumofrenalcancerpatientsbasedonhumanproteomemicroarray AT liuchengxi screeningofautoantibodiesasbiomarkersintheserumofrenalcancerpatientsbasedonhumanproteomemicroarray AT zhonghuidong screeningofautoantibodiesasbiomarkersintheserumofrenalcancerpatientsbasedonhumanproteomemicroarray AT wangchenguang screeningofautoantibodiesasbiomarkersintheserumofrenalcancerpatientsbasedonhumanproteomemicroarray AT xuhaibo screeningofautoantibodiesasbiomarkersintheserumofrenalcancerpatientsbasedonhumanproteomemicroarray AT chenwei screeningofautoantibodiesasbiomarkersintheserumofrenalcancerpatientsbasedonhumanproteomemicroarray |